Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immatics NV (IMTX)

Immatics NV (IMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 882,136
  • Shares Outstanding, K 84,658
  • Annual Sales, $ 58,440 K
  • Annual Income, $ -104,980 K
  • 60-Month Beta 0.67
  • Price/Sales 14.76
  • Price/Cash Flow N/A
  • Price/Book 3.55
Trade IMTX with:

Options Overview Details

View History
  • Implied Volatility 69.86% ( -11.72%)
  • Historical Volatility 35.92%
  • IV Percentile 40%
  • IV Rank 19.81%
  • IV High 183.85% on 10/20/23
  • IV Low 41.69% on 06/01/23
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 1.31
  • Today's Open Interest 8,287
  • Open Int (30-Day) 11,622

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -1.30
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -164.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.04 +1.89%
on 04/18/24
11.69 -12.49%
on 03/27/24
-1.03 (-9.15%)
since 03/22/24
3-Month
10.04 +1.89%
on 04/18/24
13.16 -22.26%
on 03/01/24
-1.41 (-12.11%)
since 01/24/24
52-Week
6.46 +58.36%
on 04/27/23
13.16 -22.26%
on 03/01/24
+2.88 (+39.18%)
since 04/24/23

Most Recent Stories

More News
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 10.24 (-1.73%)
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 10.24 (-1.73%)
PLX : 1.2100 (+0.83%)
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules

MRNA : 108.40 (+0.47%)
IMTX : 10.24 (-1.73%)
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 10.24 (-1.73%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 10.24 (-1.73%)
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 16.70 (-0.24%)
IMTX : 10.24 (-1.73%)
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM : 1.5400 (-1.28%)
IMTX : 10.24 (-1.73%)
Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

IMTX : 10.24 (-1.73%)
IKNA : 1.3100 (-2.96%)
Why Immatics Stock Is Soaring Today

Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.

IMTX : 10.24 (-1.73%)
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform...

IMTX : 10.24 (-1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.

See More

Key Turning Points

3rd Resistance Point 10.95
2nd Resistance Point 10.77
1st Resistance Point 10.60
Last Price 10.24
1st Support Level 10.25
2nd Support Level 10.07
3rd Support Level 9.90

See More

52-Week High 13.16
Fibonacci 61.8% 10.60
Last Price 10.24
Fibonacci 50% 9.81
Fibonacci 38.2% 9.02
52-Week Low 6.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar